Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Activity of Two Interleukins Perpetuate Chronic Autoimmune Conditions

By LabMedica International staff writers
Posted on 25 Jan 2017
A mouse model of "dry eye disease" was used to demonstrate the link between interleukins 7 and 15 and the pathogenic memory Th17 cells that mediate the autoimmune disease.

Th17 (T helper 17) cells are principal mediators of many autoimmune conditions. More...
Persistent memory Th17 cells have been revealed as crucial in mediating the chronicity of various autoimmune disorders; however, the underlying mechanisms maintaining memory Th17 cells have remained elusive.

Investigators at Harvard Medical School used a mouse model of an ocular autoimmune disease to further elucidate the mechanism controlling the behavior of Th17 cells,

The investigators reported in the November 26, 2016, online edition of the Journal of Autoimmunity that both IL-7 and IL-15 were critical for maintaining pathogenic memory Th17 cells. Neutralization of these cytokines led to substantial reduction of memory Th17 cells. Both IL-7 and IL-15 provided survival signals by activating STAT5 (Signal transducer and activator of transcription 5), and IL-15 provided additional proliferation signals by activating both STAT5 and Akt (Protein kinase B).

Topical neutralization of IL-7 or IL-15 in the eye effectively reduced memory Th17 cells at the inflammatory site and draining lymphoid tissues, while topical neutralization of IL-17 alone, the major pathogenic cytokine secreted by Th17 cells, did not diminish memory Th17 cells at the draining lymphoid tissues.

The results obtained during this study suggested that treatment to remove pathogenic memory Th17 cells via abolishing environmental IL-7 or IL-15 would be a novel strategy in the treatment of autoimmune diseases.

“We wanted to know the precise factors that maintain memory in Th17 cells so that we can better understand what is causing chronic autoimmune disorders,” said senior author Dr. Reza Dana, professor of ophthalmology at Harvard Medical School. “By selectively targeting the production and expression of IL-7 and IL-15, we may be able to prevent the development of chronic autoimmune disorders.”

“In the case of dry eye disease, many of the treatments are showing limited efficacy in patients that do not have a highly inflamed eye,” said Dr. Dana. “Targeting the chronic, immune nature of autoimmune diseases may be a better strategy for controlling these conditions.”


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Manual Pipetting Aid
Pipette Controllers macro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers from the Department of Chemistry at Aarhus University have developed and tested a new technology that can identify and measure the concentration of pharmaceuticals in under 10 minutes. Today, this process takes up to an hour. That is critical waiting time for patients suffering from a stroke. (Image Credit: Aarhus University)

Point-of-Care Blood Test Could Speed Treatment Decisions in Acute Stroke

Minutes can shape treatment decisions in emergency stroke care, particularly when physicians need to know whether a patient is taking anticoagulants before administering clot-dissolving therapy.... Read more

Microbiology

view channel
Image: The clearance also broadens QIAstat-Dx\'s infectious disease testing menu in the U.S., which already includes panels for respiratory and gastrointestinal infections, as well as meningitis and encephalitis (Photo courtesy of Qiagen)

One-Hour Molecular Panel Expands Bloodstream Infection Testing for Gram-Negative Pathogens

Bloodstream infections can progress rapidly and lead to sepsis, organ failure, and death. In the United States, about 1.7 million adults develop sepsis each year, and at least 350,000 die during hospitalization... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.